Over 20 years of treatment-free remission after Interferon-alpha monotherapy for Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a clonal malignancy characterized by the acquisition of the chromosomal translocation t(9;22), also termed Philadelphia chromosome [1], resulting in the formation of the BCR-ABL1 fusion protein. Historically, patients treated with chemotherapy such as busulfan or hydroxyurea had a grim prognosis with a median overall survival (OS) of only 4 years [2].
Source: Leukemia Research - Category: Hematology Authors: Jonathan Bloch, Olivier Spertini, Anne Stucki, Francoise Solly, Sabine Blum Tags: Letter to the Editor Source Type: research
More News: Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Mergers and Aquisitions | Translocation